On April 6, 2020, Engine Capital, L.P. announced that Harvard Bioscience, Inc. issued a press release announcing the appointment of Susan Steele to the Board of Directors of the Company as a Class III director and that Susan Steele would join the Compensation Committee upon the conclusion of the annual meeting. Engine Capital stated that effective upon the issuance of the press release, Engine Capital withdrew its nominations of Melvin L. Keating and Susan Steele for election at the annual meeting and agreed to vote the shares beneficially owned by it and its affiliates in favor of the director candidates nominated by the Company for election at the annual meeting.